Rani Therapeutics (US:RANI) Globenewswire·2025-10-30 12:00Core Insights - Rani Therapeutics is set to present preclinical data on its RaniPill® capsule at ObesityWeek® 2025, highlighting its oral delivery platform for biologics and drugs [1][2] Group 1: Presentation Details - The presentation will focus on the bioequivalence of oral Semaglutide (RT-116) in dogs compared to subcutaneous injections, demonstrating similar weight loss effects [1] - The session will take place on November 6, 2025, from 2:30 pm to 3:30 pm E.T. at the Georgia World Congress Center, with poster number 647 [1] Group 2: Company Overview - Rani Therapeutics is a clinical-stage biotherapeutics company dedicated to developing technologies for orally administered biologics and drugs [2] - The RaniPill® capsule is a proprietary and patented platform technology aimed at replacing subcutaneous injections or intravenous infusions with oral dosing [2] - The company has successfully conducted multiple preclinical and clinical studies to assess the safety, tolerability, and bioavailability of the RaniPill® capsule technology [2]